EE426 Budget Impact Analysis of Atezolizumab in 1ST Line Treatment for Patients With PD-L1 High Metastatic NSCLC From a French Payor Perspective
Dec 1, 2022, 00:00 AM
10.1016/j.jval.2022.09.672
https://www.valueinhealthjournal.com/article/S1098-3015(22)02876-5/fulltext
Section Title :
Section Order :
10205
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02876-5&doi=10.1016/j.jval.2022.09.672